Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | CDC25B | P30305 | 2/20 | 0.55 |
| ▸ | BCL2 | P10415 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30950751 | 1.00 | MEN1 (0.55) | MEN1KMT2ACDC25BBCL2MCL1 | |
| SCHEMBL29842380 | 1.00 | MEN1 (0.55) | MEN1KMT2ACDC25BBCL2MCL1 | |
| SCHEMBL16939654 | 0.88 | CDC25B (0.64) | MEN1KMT2ACDC25BALDH1A1MAPK1 | |
| SCHEMBL9149950 | 0.83 | CES1 (0.50) | MEN1KMT2ABCL2MCL1NPC1 | |
| Anthraquinone SCHEMBL29849898 | 0.81 | MAOA (0.64) | MEN1KMT2ACDC25BBCL2MCL1 | |
| SCHEMBL10824118 | 0.79 | CYP2A6 (0.55) | MEN1KMT2ACDC25BBCL2MCL1 | |
| Anthraquinone SCHEMBL27997409 | 0.78 | MEN1 (0.63) | MEN1KMT2ACDC25BBCL2MCL1 | |
| Anthraquinone SCHEMBL28961658 | 0.77 | CDC25B (0.80) | MEN1KMT2ACDC25BBCL2MCL1 | |
| Anthraquinone SCHEMBL28260408 | 0.77 | MEN1 (0.92) | MEN1KMT2ACDC25BBCL2MCL1 | |
| SCHEMBL11144928 | 0.76 | CES1 (0.73) | MEN1KMT2ACDC25BNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 439 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62195329-A | — | — | None | — | — | JP | disclosed |
| US-20260069687-A1 | THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | ASTELLAS PHARMA INC (JP) | 2026-03-12 | — | — | US | disclosed |
| EP-3738611-B1 | DIAGNOSIS AND THERAPY OF CANCER INVOLVING CANCER STEM CELLS | BioNTech SE (DE) | 2025-09-03 | — | — | EP | disclosed |
| EP-4556070-A2 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | Astellas Pharma, Inc. (JP) | 2025-05-21 | — | — | EP | disclosed |
| EP-4556071-A2 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | Astellas Pharma, Inc. (JP) | 2025-05-21 | — | — | EP | disclosed |
| US-20250092469-A1 | METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICACY OF CANCER TREATMENTS AND CANCER PROGNOSIS | GANYMED PHARMACEUTICALS GMBH (DE) | 2025-03-20 | — | — | US | disclosed |
| US-12188097-B2 | Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis | ASTELLAS PHARMA INC. (JP) | 2025-01-07 | — | — | US | disclosed |
| US-20240335533-A1 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | GANYMED PHARMACEUTICALS GMBH (DE) | 2024-10-10 | — | — | US | disclosed |
| US-12059464-B2 | Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer | ASTELLAS PHARMA INC. (JP) | 2024-08-13 | — | — | US | disclosed |
| US-20240190991-A1 | COMBINATION THERAPY WITH AN ANTI-CA19-9 ANTIBODY AND FOLFIRINOX IN THE TREATMENT OF CANCER | BioNTech SE (DE) | 2024-06-13 | — | — | US | disclosed |
| EP-0210638-A2 | Optical coating composition | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-02-04 | — | — | EP | disclosed |
| US-4613560-A | PHOTORESISTS, SEMICONDUCTORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-09-23 | — | — | US | disclosed |
| US-4601970-A | Dry photosensitive film containing crosslinked beads | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-07-22 | — | — | US | disclosed |
| EP-0186163-A2 | Photosensitive ceramic coating composition | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-07-02 | — | — | EP | disclosed |
| EP-0186114-A2 | Photosensitive conductive metal composition | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-07-02 | — | — | EP | disclosed |
| US-4598037-A | FIREABLE COATING OF SMOOTH METAL AND GLASS PARTICLES IN AN ACRYLICPHOTORESIST SYSTEM;ELECTRICAL THICK FILMS;RESOLUTIUON | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-07-01 | — | — | US | disclosed |
| US-4551415-A | DRY FILM PHOTORESIST | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-11-05 | — | — | US | disclosed |
| EP-0071483-B1 | AMINONAPHTHACENE DERIVATIVES AND THEIR PRODUCTION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-01-02 | — | — | EP | disclosed |
| EP-0072259-B1 | AMINONAPHTHACENE DERIVATIVES, THEIR PRODUCTION AND ANTI-TUMOR OR ANTI-MICROBIAL COMPOSITIONS CONTAINING THEM | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-11-21 | — | — | EP | disclosed |
| EP-0092783-A2 | Photosensitive coatings containing crosslinked beads | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190991-A1 | COMBINATION THERAPY WITH AN ANTI-CA19-9 ANTIBODY AND FOLFIRINOX IN THE TREATMENT OF CANCER | CA9, CA14, CA13 | MEN1 1506/4885KMT2A 2507/4885CDC25B 2273/4885 |
| US-20250092469-A1 | METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICACY OF CANCER TREATMENTS AND CANCER PROGNOSIS | TP53, MKI67, TSG101 | MEN1 2987/4885KMT2A 3412/4885CDC25B 549/4885 |
| US-12188097-B2 | Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis | TP53, MKI67, TSG101 | MEN1 2987/4885KMT2A 3412/4885CDC25B 549/4885 |
| US-12059464-B2 | Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer | EPCAM, KRT18, CALU | MEN1 1562/4885KMT2A 2238/4885CDC25B 1046/4885 |
| US-20240335533-A1 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | EPCAM, KRT18, CALU | MEN1 1562/4885KMT2A 2238/4885CDC25B 1046/4885 |
| US-20260069687-A1 | THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | EPCAM, VSIG8, ICAM1 | MEN1 2443/4885KMT2A 2524/4885CDC25B 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.